Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179348525> ?p ?o ?g. }
- W3179348525 endingPage "7474" @default.
- W3179348525 startingPage "7474" @default.
- W3179348525 abstract "Hutchinson–Gilford progeria syndrome (HGPS) is an ultra-rare multisystem premature aging disorder that leads to early death (mean age of 14.7 years) due to myocardial infarction or stroke. Most cases have a de novo point mutation at position G608G within exon 11 of the LMNA gene. This mutation leads to the production of a permanently farnesylated truncated prelamin A protein called “progerin” that is toxic to the cells. Recently, farnesyltransferase inhibitor (FTI) lonafarnib has been approved by the FDA for the treatment of patients with HGPS. While lonafarnib treatment irrefutably ameliorates HGPS disease, it is however not a cure. FTI has been shown to cause several cellular side effects, including genomic instability as well as binucleated and donut-shaped nuclei. We report that, in addition to these cellular stresses, FTI caused an increased frequency of cytosolic DNA fragment formation. These extranuclear DNA fragments colocalized with cGAs and activated the cGAS-STING-STAT1 signaling axis, upregulating the expression of proinflammatory cytokines in FTI-treated human HGPS fibroblasts. Treatment with lonafarnib and baricitinib, a JAK-STAT inhibitor, not only prevented the activation of the cGAS STING-STAT1 pathway, but also improved the overall HGPS cellular homeostasis. These ameliorations included progerin levels, nuclear shape, proteostasis, cellular ATP, proliferation, and the reduction of cellular inflammation and senescence. Thus, we suggest that combining lonafarnib with baricitinib might provide an opportunity to reduce FTI cellular toxicity and ameliorate HGPS symptoms further than lonafarnib alone." @default.
- W3179348525 created "2021-07-19" @default.
- W3179348525 creator A5030753581 @default.
- W3179348525 creator A5037881146 @default.
- W3179348525 creator A5049324631 @default.
- W3179348525 creator A5055798294 @default.
- W3179348525 date "2021-07-12" @default.
- W3179348525 modified "2023-10-06" @default.
- W3179348525 title "Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells" @default.
- W3179348525 cites W1254790682 @default.
- W3179348525 cites W1563425172 @default.
- W3179348525 cites W1964551999 @default.
- W3179348525 cites W1968178474 @default.
- W3179348525 cites W1974662012 @default.
- W3179348525 cites W1978274156 @default.
- W3179348525 cites W1983120861 @default.
- W3179348525 cites W1992900610 @default.
- W3179348525 cites W1993935340 @default.
- W3179348525 cites W1998129814 @default.
- W3179348525 cites W2007872313 @default.
- W3179348525 cites W2010417927 @default.
- W3179348525 cites W2016268789 @default.
- W3179348525 cites W2021120405 @default.
- W3179348525 cites W2021687666 @default.
- W3179348525 cites W2024153799 @default.
- W3179348525 cites W2026463310 @default.
- W3179348525 cites W2029275361 @default.
- W3179348525 cites W2032019813 @default.
- W3179348525 cites W2035471726 @default.
- W3179348525 cites W2036464895 @default.
- W3179348525 cites W2036699032 @default.
- W3179348525 cites W2039953525 @default.
- W3179348525 cites W2043446752 @default.
- W3179348525 cites W2046594411 @default.
- W3179348525 cites W2053206914 @default.
- W3179348525 cites W2063456960 @default.
- W3179348525 cites W2070353676 @default.
- W3179348525 cites W2073460054 @default.
- W3179348525 cites W2076421086 @default.
- W3179348525 cites W2080628130 @default.
- W3179348525 cites W2090787210 @default.
- W3179348525 cites W2094806530 @default.
- W3179348525 cites W2099610218 @default.
- W3179348525 cites W2101185010 @default.
- W3179348525 cites W2103286704 @default.
- W3179348525 cites W2104908670 @default.
- W3179348525 cites W2105110037 @default.
- W3179348525 cites W2108244474 @default.
- W3179348525 cites W2111175126 @default.
- W3179348525 cites W2111819985 @default.
- W3179348525 cites W2115852450 @default.
- W3179348525 cites W2118898403 @default.
- W3179348525 cites W2122103252 @default.
- W3179348525 cites W2122860817 @default.
- W3179348525 cites W2123704670 @default.
- W3179348525 cites W2127708563 @default.
- W3179348525 cites W2127804300 @default.
- W3179348525 cites W2129155846 @default.
- W3179348525 cites W2130458932 @default.
- W3179348525 cites W2141334538 @default.
- W3179348525 cites W2143185290 @default.
- W3179348525 cites W2143505819 @default.
- W3179348525 cites W2143571321 @default.
- W3179348525 cites W2149619603 @default.
- W3179348525 cites W2150748567 @default.
- W3179348525 cites W2154171253 @default.
- W3179348525 cites W2156516895 @default.
- W3179348525 cites W2158608461 @default.
- W3179348525 cites W2159659449 @default.
- W3179348525 cites W2163087340 @default.
- W3179348525 cites W2166403801 @default.
- W3179348525 cites W2191745121 @default.
- W3179348525 cites W2193792657 @default.
- W3179348525 cites W2223535266 @default.
- W3179348525 cites W2272329318 @default.
- W3179348525 cites W2317009399 @default.
- W3179348525 cites W2565668513 @default.
- W3179348525 cites W2593565645 @default.
- W3179348525 cites W2736686010 @default.
- W3179348525 cites W2742007963 @default.
- W3179348525 cites W2762611634 @default.
- W3179348525 cites W2790056846 @default.
- W3179348525 cites W2795875233 @default.
- W3179348525 cites W2795876990 @default.
- W3179348525 cites W2800246801 @default.
- W3179348525 cites W2801288131 @default.
- W3179348525 cites W2807837656 @default.
- W3179348525 cites W2808901157 @default.
- W3179348525 cites W2810369524 @default.
- W3179348525 cites W2831198025 @default.
- W3179348525 cites W2913468595 @default.
- W3179348525 cites W2954445592 @default.
- W3179348525 cites W2980326022 @default.
- W3179348525 cites W2985080809 @default.
- W3179348525 cites W2995236678 @default.
- W3179348525 cites W3012106404 @default.
- W3179348525 cites W3024939104 @default.
- W3179348525 cites W3120913371 @default.